Welcome to our dedicated page for Kiniksa Pharmaceuticals International, plc SEC filings (Ticker: KNSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kiniksa Pharmaceuticals International, plc filings document regulatory disclosures for a Nasdaq-listed biopharmaceutical company incorporated in England and Wales. Form 8-K reports cover operating results and financial condition, ARCALYST portfolio execution, investor presentations, and executive appointments or consulting arrangements.
Proxy materials cover annual meeting matters, director elections, executive compensation, shareholder voting procedures, and board governance. The filing record also identifies the company’s Class A ordinary shares, Nasdaq Global Select Market listing, and recurring disclosures tied to its commercial ARCALYST franchise and cardiovascular-focused development portfolio.
Kiniksa Pharmaceuticals International reported Form 4 transactions for John F. Paolini, its Chief Medical Officer and a director. The filing shows multiple equity award grants and option/RSU issuances on September 1 and 2, 2025, including 9,828 RSUs, a 39,364-share option exercisable through 08/31/2035 at a $33.49 exercise price, and several additional RSU grants tied to prior grant dates. The report also discloses sales of Class A ordinary shares on September 1 (2,841 shares at $33.49) and September 2 (835 shares at $34.28). Post-transactions beneficial ownership totals are shown for each line and all holdings are reported as direct.
Mark Ragosa, Chief Financial Officer of Kiniksa Pharmaceuticals International, plc (KNSA), reported multiple equity transactions on Form 4 covering September 1-2, 2025. The filing shows grant activity including 12,275 Restricted Share Units (RSUs), a 39,363-share option with a $33.49 exercise price and several additional RSU grants and awards. It also discloses sales of Class A Ordinary Shares: 2,920 shares sold at $33.49 and 900 shares sold at $34.28. Following the reported transactions, the filing lists varying beneficial ownership totals for each line item, with direct ownership reported for all items. The form is signed by an attorney-in-fact on behalf of the reporting person.
Kiniksa Pharmaceuticals director and Chairman & CEO Sanj K. Patel reported multiple transactions on Form 4 covering September 1-2, 2025. The filing shows grants of 34,435 restricted share units (RSUs), a 137,638-share option with a $33.49 exercise price, and additional RSU grants and deliveries on those dates. The report also discloses open-market disposals: 10,983 Class A shares sold at $33.49 and 3,177 Class A shares sold at $34.28. Following the transactions, Mr. Patel beneficially owns 109,795 shares indirectly held by The Marina 2016 Irrevocable Trust and reports various direct holdings reflected in the table. Vesting schedules are specified: RSUs generally vest over four years with 25% annual vesting and the option vests 25% after one year then monthly over three years.
Kiniksa Pharmaceuticals International, plc reported a Form 144 notice for the proposed sale of 11,000 Class A ordinary shares to be executed through Charles Schwab & Co., Inc. on 09/03/2025 with an aggregate market value of $383,203.00. The shares were acquired the same day via an employee stock option exercise and the transaction will use a broker payment for a cashless exercise. The filing lists 43,472,928 shares outstanding, and shows prior sales by Michael R. Megna of 15,211 shares on 06/03/2025 (gross proceeds $437,330) and 17,000 shares on 08/04/2025 (gross proceeds $549,936). The filer certifies no undisclosed material adverse information.
Kiniksa Pharmaceuticals International, plc filed a Form 8-K to let investors know it has posted a new investor presentation on its website at investors.kiniksa.com. The company plans to use this presentation, in whole or in part and potentially with modifications, in upcoming meetings with investors, analysts and other audiences.
The investor presentation is furnished as Exhibit 99.1 to this report, with an additional cover page interactive data file listed as Exhibit 104. The filing is informational and does not announce any specific transaction or financial results.
Kiniksa Pharmaceuticals insider transactions by COO Eben Tessari show a mix of purchases and sales executed under a 10b5-1 plan. The reporting person exercised 6,500 vested options at an exercise price of $8.83 on 08/18/2025, acquiring 6,500 Class A ordinary shares. On the same date the reporting person sold 16,100 shares at a weighted-average price of $33.77 and an additional 100 shares at $34.44, reducing beneficial ownership to 40,215 shares. The Form 4 notes the trades were effected pursuant to a 10b5-1 plan executed April 29, 2024, and the option is fully vested and exercisable through 09/16/2029.
Kiniksa Pharmaceuticals International, plc (KNSA) Form 144 notice reports a proposed sale of 16,200 Class A ordinary shares through Charles Schwab, with an aggregate market value of $547,070, slated for 08/18/2025 on NASDAQ. The filing documents the acquisition history for those shares, including founders' shares from 09/16/2015, two performance award lapses in 03/2022 and 03/2023, and an 08/18/2025 cashless option exercise. The filer, identified by past sales as Eben Tessari at a Lexington, MA address, sold 257,681 shares across seven transactions in May–August 2025, generating total gross proceeds of $8,111,307. The notice includes the seller's representation about lack of undisclosed material adverse information.
Insider transactions by Thomas Malley, a director of Kiniksa Pharmaceuticals International, plc (KNSA) are reported for August 12–14, 2025. The Form 4 shows multiple option exercises and open-market sales. Mr. Malley exercised stock options at strike prices ranging from $1.86 to $15.47, converting options into Class A ordinary shares. The filing reports open-market sales totaling 207,898 shares sold across three days at weighted-average sale prices in the low $30s (individual weighted averages reported at $32.4, $33.32 and $33.09). After these transactions, Mr. Malley directly beneficially owned 12,546 Class A shares and indirectly beneficially owned 71,967 shares through Mossrock Capital, LLC. The filing notes all reported options are fully vested and exercisable and includes broker execution price ranges for the sales.
Kiniksa Pharmaceuticals International, plc (KNSA) Form 144 notifies proposed sales of 78,233 Class A ordinary shares through Charles Schwab & Co., with an aggregate market value of $2,588,711.00 and an approximate sale date of 08/14/2025 on NASDAQ. The filing states these shares were acquired the same day by employee stock option exercise and disposed via a broker cashless exercise. The filer previously sold 49,407 shares on 08/12/2025 for $1,600,641.00 and 50,129 shares on 08/13/2025 for $1,670,468.00. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Kiniksa Pharmaceuticals International, plc (KNSA) filed a Form 144 proposing the sale of 50,129 Class A ordinary shares. The filing shows the shares were acquired and are to be sold on 08/13/2025 via an employee stock option exercise with payment described as Broker Payment for Cashless Exercise. The broker listed is Charles Schwab & Co., Inc. and the aggregate market value is $1,670,468.00. The filing reports 43,472,928 shares outstanding, so the offered block equals about 0.12% of outstanding shares. The document also discloses a sale by Thomas Malley of 49,407 shares on 08/12/2025 for $1,600,641.00. Several identifying fields (CIK/CCC and filer contact/name fields) are not populated in the provided content.